Bellicum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Jefferies Raises Price Target on Bellicum Pharma (BLCM) to $22; Reiterates Buy
August 9, 2016 9:50 AM EDTJefferies reiterated a Buy rating on Bellicum Pharmaceuticals (NASDAQ: BLCM), and raised the price target to $22.00 (from $20.00), following the company's 2Q earnings report. BLCM reported a Q2 GAAP EPS of ($0.61) vs. estimates of ($0.59).
Analyst Biren Amin commented, "BLCM reported 2Q financial results... More
Bellicum Pharma (BLCM) Misses Q2 EPS by 4c
August 8, 2016 5:06 PM EDTBellicum Pharma (NASDAQ: BLCM) reported Q2 EPS of ($0.61), $0.04 worse than the analyst estimate of ($0.57).
For earnings history and earnings-related data on Bellicum Pharma (BLCM) click here.
... More